The Phase 3 Clinical Trial of the M72/ASO1E tuberculosis (TB) Vaccine Candidate Has Reached Full Enrollment

We’re glad to announce that the Phase 3 clinical trial of the M72/AS01E tuberculosis (TB) vaccine candidate has reached full enrollment eleven months ahead of schedule– with approximately 20,000 participants enrolled.

With the M72 trial at full enrollment, we take another step closer to the critically important goal of a safe and effective tuberculosis vaccine. A TB vaccine that can help prevent adolescents and adults from the disease is urgently needed.

Patrice Matchaba, CEO of the Gates MRI

Fifty four trial sites have activated across five countries to assess the efficacy and safety of this M72/AS01E vaccine candidate.

Thanks to the support of our clinical trial partners—Gates Foundation, GSK and Wellcome Trust— as well as the health authorities, community advisory board members, participants, and their families across 54 trial sites we are closer to understanding the safety and efficacy of this investigational vaccine candidate.

A novel TB vaccine is critical to the vision of a world without TB. If proven well tolerated and efficacious, the M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years.